Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. - Wikidata - awgldk - TriplyDB

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

http://www.wikidata.org/entity/Q34457943

about

CETP Inhibition: Past Failures and Future Hopes Precision medicine: from pharmacogenomics to pharmacoproteomics Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes Translational and Therapeutic Approaches to the Understanding and Treatment of Dyslipidemia Evidence-based goals in LDL-C reduction.Pharmacogenetic Markers of Drug Efficacy and Toxicity.Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.Dysfunctional HDL and atherosclerotic cardiovascular disease.HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease.Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.Mendelian randomisation in cardiovascular research: an introduction for clinicians.Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.Cholesteryl Ester Transfer Protein Inhibitors: Trials and Tribulations.Cholesteryl ester transfer protein inhibitors: challenges and perspectives.Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs.Combined crystal structure prediction and high-pressure crystallization in rational pharmaceutical polymorph screening.Anacetrapib as a potential cardioprotective strategy.Personalized Management of Cardiovascular Disorders.Design, Synthesis and Biological Evaluation of N,N-Substituted Amine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors.Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies.Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use.Elevated Adenylyl Cyclase 9 Expression Is a Potential Prognostic Biomarker for Patients with Colon Cancer.Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena.Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Tria ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.No evidence for association of MTHFR 677C>T and 1298A>C variants with placental DNA methylation.Unravelling HDL-Looking beyond the Cholesterol Surface to the Quality Within The use of mechanistic evidence in drug approval

P2860

Q26753158-C294F5DC-25C8-486E-98E6-101B8A2B12C8 Q28076871-9CE19C0B-84E3-4A2A-8BE2-83760AC57A05 Q33867662-435C087F-5090-49A1-AAA8-E0C47B174F93 Q34534212-584B8537-03E9-4D72-B49F-18F943753F6E Q37036108-BE7554C2-654E-4C6F-BA11-068C3C8EA2C8 Q37714588-94373191-F885-452E-9307-C3593898B803 Q38419534-96DFBCFC-604D-4F12-B697-138C4FCB2E91 Q38528288-0ABE8BDC-B3AF-4A8A-B406-6DA7488F0304 Q38577283-6F0E74BE-6C66-4CA0-9CD0-19DDACF8017C Q38630971-0B5AC237-A088-4B47-998B-847865597910 Q38644870-A075D7BE-79F4-43C6-A6C4-4D6971886980 Q38653425-ADF4675A-061B-4F8E-AE04-232BA6742008 Q38696985-CE3D3410-D241-4B32-AF3D-2F64B6E78E38 Q38707328-61A89472-DB07-4D7A-9E32-08D20B9BAA88 Q38735373-68635EBE-26C2-41B5-8E55-53FE246305B6 Q38786058-781D2540-7965-4D4B-83F9-98986839B4E7 Q38832478-1697827D-EFB2-4B0E-A2C6-79B179A900A9 Q38832774-BA4603C9-8AC5-4444-90AE-65D95D766BA5 Q38839105-24ADD68D-FB79-4289-AF78-03B4DF622BC4 Q39158851-68583F73-2442-4E0C-A7B7-CA43ABA38FF4 Q39255756-BB7CC75F-51A5-4E19-8F32-4500C7FD2CFE Q42044900-DE846495-D5A2-4DC9-9E41-7B122DD811A8 Q47162079-5719B8C0-6BDF-4DB5-9B6D-6630C6E18A83 Q47690029-387B4ABF-2A08-48BD-8AE6-095E1DB627A8 Q47708252-FB93FD54-FFF1-43C6-98DA-C882E5F3E20C Q47750262-C6606FAC-3CEE-438D-839A-8686BF8E3854 Q48385505-9728BAF2-2121-414C-B0EC-FC73B814D02F Q49226934-2488CDCA-C72D-4F7E-903F-7A7ED101366F Q50082577-E9D67EB9-9F06-4546-A5C0-7AB3324F94F0 Q50119076-815C7D8F-4AF0-4374-890A-8CE8871355DA Q51741683-DAEB2EB9-7E53-45D9-BA27-B33BF555D42E Q52689990-D36CD6AC-881D-4663-BB35-97124D4F192D Q57176950-C7B620E2-5315-42A5-9BEF-15575361BDBC Q57660586-92D8630C-9FDE-4178-8DC0-0605A5948E0F

P2860

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

http://www.wikidata.org/entity/Q34457943

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

@ast

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

@en

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

@nl

type

label

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

@ast

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

@en

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

@nl

prefLabel

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

@ast

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

@en

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

@nl

P1433

Q34457943-39D4A340-E9CF-4583-9491-8EA32A0356B6

P1476

Q34457943-131C84CD-61B8-423B-9B57-6434F317B7CB

P2093

Q34457943-0BA1A8CC-0BE9-4349-A4E8-FC385F17956B

Q34457943-20B48006-9C13-4606-BCB7-B2E88D1701D0

Q34457943-2E912EFB-166D-41BA-8748-ECC0FE761E77

Q34457943-35AF8077-8F7F-4F10-BF31-4B37934C1158

Q34457943-38EF5C12-D582-4929-B5C4-1C6D87F33203

Q34457943-47A024C8-810E-4B1A-9950-39BFDCA05BC6

Q34457943-4BE4D395-838E-4E4C-A9B0-BFBB3CAC0615

Q34457943-5416C1A9-62AF-4B11-80DF-018940575FC1

Q34457943-58732E31-2E38-45D5-AB0C-9DF30AE4701E

Q34457943-605CCBB3-7421-41FF-B2B2-90851BE36053

P304

Q34457943-6A45F11F-72C6-4603-A632-D705A4CFA2E1

P31

Q34457943-B884A196-70AB-408A-83DD-AE426D371E19

P356

Q34457943-0CE33F0D-2579-45D3-96D7-824A286E1103

P433

Q34457943-06DEF4B8-832D-44CA-9BD8-CFA1D6838D08

P478

Q34457943-FF3958D2-9D85-4D58-B5D3-8EFC9ABF48D2

P50

Q34457943-49B48E75-B44E-40B1-A7D8-5B429A16848F

Q34457943-4C0D8518-16CF-4E85-9245-233DE43219B6

Q34457943-8F5E5547-2EF2-4BCC-985D-CBCDC610F6ED

Q34457943-A2A756E3-BA9B-49CD-B8F4-FA38D1F1A529

P577

Q34457943-C246D2C2-224F-4A05-BAD4-C0E8B6B2E536

P698

Q34457943-BBF4FBA7-3D6A-4741-8B58-7706BE3B139F

P921

Q34457943-78D1932E-2FEC-4200-9372-AE3765D54E12

Q34457943-DFDC1203-36CE-4B89-9B7A-D866F33B53C1

P356

CIRCGENETICS.114.000663

P1433

Circulation: Cardiovascular Genetics

P1476

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

@en

P2093

Amina Barhdadi

http://www.w3.org/2001/XMLSchema#string

Anders G Olsson

http://www.w3.org/2001/XMLSchema#string

David Rhainds

http://www.w3.org/2001/XMLSchema#string

Eric J Niesor

http://www.w3.org/2001/XMLSchema#string

Fouzia Laghrissi-Thode

http://www.w3.org/2001/XMLSchema#string

Gabriela Suchankova

http://www.w3.org/2001/XMLSchema#string

Gregory G Schwartz

http://www.w3.org/2001/XMLSchema#string

Géraldine Asselin

http://www.w3.org/2001/XMLSchema#string

Ian Mongrain

http://www.w3.org/2001/XMLSchema#string

Jean C Grégoire

http://www.w3.org/2001/XMLSchema#string

P304

372-382

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCGENETICS.114.000663

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Claude Tardif

Marie-Pierre Dubé

Louis-Philippe Lemieux Perreault

P577

2015-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25583994

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

pharmacogenomics